NCT06151106

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

A Multicenter, Prospective and Single-arm Clinical Study on the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma (R/R PTCL) With Chidamide and Duvalisib

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: The First Affiliated Hospital of Xiamen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.

Detailed description

This is a Phase 2, open-label clinical trial study that aims to evaluate the efficacy (Overall Response Rate, Complete Response, Partial Response, Overall Survival, Progression Free Survival) and adverse effects of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.

Conditions

• Peripheral T Cell Lymphoma
• Relapsed Peripheral T-Cell Lymphoma
• Refractory T-Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Chidamide combined with Duvillisib	Specified dose on specified days

Timeline

• Start date: 2023-11-22
• Primary completion: 2026-12-31
• Completion: 2027-12-25
• First posted: 2023-11-30
• Last updated: 2025-02-19

Locations

1 site across 1 country: China